He paused, observing everyone's reactions: "This research is fully open and transparent, and all data is shared. If successful, we can establish an open-source tumor-targeted apoptosis therapy platform, allowing any qualified institution to develop their own treatment plans based on it. This is more beneficial to global patients than having one company monopolize a technology, isn't it?"
The meeting room fell silent, and the experts exchanged glances. From a scientist's perspective, they instinctively welcomed the exploration of more research paths; but from a practical standpoint, they also understood the implications of the competitive dynamics behind this.
"Where will the funding come from?" Professor Chen asked.
"Our international foundation!" Wu Dechang said, "We are not pursuing short-term commercial returns. Our goal is to establish a public technology platform."
"What about Ruixing and Sanbo..."
